Velocity Bioworks successfully completes initial evaluation of LarmorBio’s BioScan-NMR^™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, viability, and phenotype within bioreactors

Milestone achieved less than six months after Valion Bio secured exclusive rights to LarmorBio’s next-generation NMR technology

First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics

Company Prepares to Scale Business with Proprietary Microscale Magnetic Resonance Technology

Proprietary Methodology Shows Potential to Improve Yield, Quality and Function of Cell Derived Therapies